BidaskClub downgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a buy rating to a hold rating in a report released on Wednesday morning.
Several other research firms also recently commented on RARE. Wedbush reissued an outperform rating and set a $88.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Monday, January 7th. Cowen reissued a buy rating and set a $69.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, February 26th. Zacks Investment Research raised shares of Ultragenyx Pharmaceutical from a hold rating to a buy rating and set a $51.00 price objective for the company in a report on Wednesday, December 12th. Raymond James reissued an outperform rating and set a $80.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, February 22nd. Finally, Credit Suisse Group reissued a hold rating and set a $59.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 20th. Seven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $76.16.
Get Ultragenyx Pharmaceutical alerts:RARE opened at $62.78 on Wednesday. Ultragenyx Pharmaceutical has a 52 week low of $37.44 and a 52 week high of $90.98. The stock has a market cap of $3.22 billion, a price-to-earnings ratio of -8.50 and a beta of 2.26.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, February 19th. The biopharmaceutical company reported ($1.73) EPS for the quarter, beating the consensus estimate of ($1.74) by $0.01. Ultragenyx Pharmaceutical had a negative net margin of 383.75% and a negative return on equity of 35.26%. The business had revenue of $16.26 million during the quarter, compared to the consensus estimate of $13.30 million. On average, equities research analysts forecast that Ultragenyx Pharmaceutical will post -6.82 earnings per share for the current fiscal year.
Several large investors have recently made changes to their positions in the stock. Capital Research Global Investors lifted its holdings in shares of Ultragenyx Pharmaceutical by 1.7% in the 3rd quarter. Capital Research Global Investors now owns 5,856,138 shares of the biopharmaceutical company’s stock valued at $447,058,000 after acquiring an additional 100,575 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 2.8% in the 4th quarter. BlackRock Inc. now owns 4,476,812 shares of the biopharmaceutical company’s stock valued at $194,652,000 after acquiring an additional 123,409 shares during the last quarter. Capital International Investors lifted its holdings in shares of Ultragenyx Pharmaceutical by 20.9% in the 3rd quarter. Capital International Investors now owns 4,359,891 shares of the biopharmaceutical company’s stock valued at $332,834,000 after acquiring an additional 755,127 shares during the last quarter. Federated Investors Inc. PA lifted its holdings in shares of Ultragenyx Pharmaceutical by 4.7% in the 3rd quarter. Federated Investors Inc. PA now owns 1,484,271 shares of the biopharmaceutical company’s stock valued at $113,309,000 after acquiring an additional 66,720 shares during the last quarter. Finally, First Trust Advisors LP lifted its holdings in shares of Ultragenyx Pharmaceutical by 16.5% in the 4th quarter. First Trust Advisors LP now owns 1,471,934 shares of the biopharmaceutical company’s stock valued at $64,000,000 after acquiring an additional 208,468 shares during the last quarter. 98.35% of the stock is owned by hedge funds and other institutional investors.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Recommended Story: Price-Sales Ratio
No comments:
Post a Comment